Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification

doi:10.4254/wjh.v7.i6.825

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9244)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

692

WORD

350

HTML

3418

Tables (1-2)

244

Sum=4704

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

616

Download

1130

Sum=1746

Publishing Process of This Article

Item

Count

Browse

1213

Download

1581

Sum=2794

Apr 28, 2015 (publication date) through Jan 8, 2025

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. Apr 28, 2015; 7(6): 825-830
Published online Apr 28, 2015. doi: 10.4254/wjh.v7.i6.825

Table 1 Immunosuppressive regimens known to increase risk of hepatitis B virus reactivation

HBsAg-positive	HBsAg-negative
	Anti-HBc positive
Corticosteroids	Anti-CD20 (e.g., rituximab)
Anti-CD20 (e.g., rituximab)	HSCT
HSCT	Anti-TNF
Anti-TNF	TACE for hepatocellular carcinoma
Anthracyclines	Methotrexate
TACE for hepatocellular carcinoma
Methotrexate
Ustekinumab
Tyrosine kinase inhibitors

HBsAg: Hepatitis B surface antigen; Anti-HBc: Antibody to hepatitis B core antigen; Anti-CD20: Antibody against CD20; Anti-TNF: Antibody against tumor necrosis factor; TACE: Transarterial chemo-embolization; HSCT: Hematopoietic stem cell transplantation.

Citation: Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. World J Hepatol 2015; 7(6): 825-830
URL: https://www.wjgnet.com/1948-5182/full/v7/i6/825.htm
DOI: https://dx.doi.org/10.4254/wjh.v7.i6.825